Renin-Angiotensin-Aldosterone System Blockade Effects on the Kidney in the Elderly
Authors:
- Faruk TurgutFaruk Turgut
- Rasheed A. BalogunRBRasheed A. Balogun
- Emaad M. Abdel-RahmanEAEmaad M. Abdel-Rahman
Open Access
- 1 July 2010
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 5 (7) , 1330-1339
Abstract
The proportion of the population that is elderly (age ≥65 years) is growing across the world. The increasing longevity of humans results in a higher number of elderly patients’ presenting with multiple chronic diseases such as hypertension, diabetes, and chronic kidney disease (CKD). These problems increase morbidity and mortality in the elderly. Overactivity of the renin-angiotensin-aldosterone system (RAAS) is associated with the development of hypertension, cardiovascular events, and CKD, so targeting the RAAS is a logical therapeutic approach. Elderly patients present special concerns regarding the benefits versus risks of using RAAS blockers. Plasma renin activity declines with age, which has been attributed to the effect of age-associated nephrosclerosis. Plasma aldosterone is also reduced with age, resulting in a greater risk for hyperkalemia in older individuals, especially when coupled with the age-associated decline in GFR. Moreover, the elderly have a higher frequency of concurrent conditions and are on many medications, which may further increase the risk for adverse effects of RAAS blocking agents. Unfortunately, there is a paucity of literature that is specifically aimed at studying elderly using the RAAS blockers. We present in our in-depth review data regarding benefits and limitations of the use of the RAAS blockades on the various sites along the RAAS pathway for elderly patients. Specific attention was given to the role of combination RAAS blockade therapy and higher monotherapy dosing in the treatment of hypertension in the elderly.Keywords
This publication has 72 references indexed in Scilit:
- Diabetes and Drug-Associated Hyperkalemia: Effect of Potassium MonitoringJournal of General Internal Medicine, 2010
- The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunctionAmerican Heart Journal, 2009
- Olmesartan Medoxomil in Elderly Patients with Essential or Isolated Systolic HypertensionDrugs & Aging, 2009
- Regulation of renal 12(S)-hydroxyeicosatetraenoic acid in diabetes by angiotensin AT1and AT2receptorsAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2008
- Prevalence of Chronic Kidney Disease in the United StatesJAMA, 2007
- Aliskiren Reduces Blood Pressure and Suppresses Plasma Renin Activity in Combination With a Thiazide Diuretic, an Angiotensin-Converting Enzyme Inhibitor, or an Angiotensin Receptor BlockerHypertension, 2007
- Prevention and Treatment of Diabetic Renal Disease in Type 2 DiabetesJournal of the American Society of Nephrology, 2006
- Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failureAmerican Heart Journal, 2004
- ACE Inhibitors and Appearance of Renal Events in Hypertensive NephrosclerosisHypertension, 2001
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999